Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:486-493
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borries, M.
Right arrow Articles by Leschke, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borries, M.
Right arrow Articles by Leschke, M.

CLINICAL STUDIES

Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina

Markus Borries, MDa,a, Michael Heins, MD*, Yuriko Fischer, MDa, Hugo Stiegler, MDa, Ansgar Peters, MDa, Hans Reinauer, MD*, Frank C. Schoebel, MD, Bodo E. Strauer, MD, FACCa and Matthias Leschke, MDa

a Klinik für Kardiologie, Pneumologie und AngiologieHeinrich-Heine-Universität, Düsseldorf, Germany
* Institut für Klinische Chemie und Laboratoriumsdiagnostik, Heinrich-Heine-Universität, Düsseldorf, Germany

Manuscript received September 14, 1998; revised manuscript received March 15, 1999, accepted April 22, 1999.

Reprint requests and correspondence: Dr. Markus Borries, Heinrich-Heine-Universität Düsseldorf, Klinik für Kardiologie, Pneumologie und Angiologie, Moorenstr. 5, 40225 Düsseldorf, Germany
Markus.Borries{at}uni-duesseldorf.de

OBJECTIVES

This study investigated parameters of endogenous fibrinolysis, activation of coagulation and platelets, and endothelin levels before and after elective percutaneous transluminal coronary angioplasty (PTCA) in patients with stable coronary artery disease (CAD).

BACKGROUND

Abrupt vessel closure is a serious short-term complication after PTCA and is often unforeseeable. Detailed insight into the effect of PTCA on hemostasis, platelets and the release of vasoconstrictive substances, which are among the mainly discussed mechanisms of abrupt vessel closure, is needed to enhance the safety of coronary intervention.

METHODS

Plasma levels of markers of platelet activity, coagulation, endogenous fibrinolysis and endothelins were determined in 20 patients with stable CAD undergoing elective PTCA. The blood specimens were drawn before, immediately after, 1 h after intervention and on the next morning.

RESULTS

All patients showed an initially uncomplicated PTCA. Regarding the efficacy of anticoagulation after receiving 15.000 IU heparin during PTCA, two groups were compared. In eight patients with ineffective anticoagulation production of thrombin and platelet activation directly after and 1 h after PTCA was significantly higher compared with 12 patients with effective anticoagulation. Despite the strong activation of coagulation, only a low fibrinolytic response could be observed. Endothelins rose significantly after PTCA in both groups but stayed longer on higher levels in patients with distinct thrombin generation. Three of the eight patients without sufficient heparin treatment suffered abrupt vessel closure.

CONCLUSIONS

Initially uncomplicated dilation of coronary arteries leads to systemically measurable activation of coagulation and platelets in patients with ineffective doses of heparin and release of endothelins in all patients. Therefore, individual adjustment of anticoagulation and platelet inhibition in combination with effective antivasospastic substances are needed in every patient before, during and after initially uncomplicated PTCA to prevent this serious complication.

Abbreviations and Acronyms
  APTT = activated partial thromboplastin time
  AT = antithrombin
  beta-TG = beta-thromboglobulin
  CAD = coronary artery disease
  F1+2 = prothrombin fragment 1+2
  PAI = plasminogen activator inhibitor
  PAP = plasmin-{alpha}2-antiplasmin complex
  PTCA = percutaneous transluminal coronary angioplasty
  TAT = thrombin-antithrombin complex
  t-PA = tissue plasminogen activator






 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement